ArticleFrontiers in pharmacology2025
Preventive effect of sodium bicarbonate Ringer's solution on post-contrast acute kidney injury in patients undergoing percutaneous coronary intervention.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update on Contrast-Induced Nephropathy: Recent Developments in Its Prevention, Early Diagnosis, and Therapy.Medicina (Kaunas, Lithuania) · 2026Review
- New insights into contrast-associated acute kidney injury: the key role of endothelial dysfunction.Frontiers in nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-contrast acute kidney injury (PC-AKI) is a common complication of coronary angiography (CAG) and percutaneous coronary interventions (PCI). Sodium bicarbonate Ringer's solution (BRS) has been shown to reduce the incidence of postoperative AKI and the risk of acid-base disorder in surgical and critically ill patients. There is no research data of BRS in the field of PC-AKI. Therefore, this study aimed to evaluate the efficacy and safety of BRS in the prevention of PC-AKI. Methods: Patients with coronary atherosclerotic heart disease and stage 2-3b chronic kidney disease (CKD) who underwent CAG or PCI were prospectively enrolled and randomly assigned to BRS group or normal saline (NS) group from February 2024 to October 2024. The patients were given BRS or NS for hydration at 1mL/kg/h from 3 h before to 4 h after CAG/PCI. Serum creatinine (Scr), cystatin C (Cys-C) and neutrophil gelatinase-associated apolipoprotein (NGAL) were measured within 3 days before and 48 h after iodinated contrast agent exposure. The primary endpoint was PC-AKI, and the secondary endpoints were the need of renal replacement therapy (RRT) and major adverse cardiovascular events (MACEs) within 30 days after CAG/PCI. The correlation between BRS and PC-AKI was analyzed by multivariate logistic regression. Results: The baseline characteristics of patients in the two groups were similar, and the changes of Cys-C, NGAL, and electrolytes before and after CAG/PCI were not statistically significant. PC-AKI occurred in 1 patient (1.3%) in BRS group and 7 patients (9.3%) in NS group, and the difference was statistically significant ( Conclusion: BRS might be more suitable than NS in reducing the incidence of PC-AKI for patients with mild-to-moderate renal dysfunction who underwent CAG/PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.